1
|
Campitiello R, Soldano S, Gotelli E, Hysa E, Montagna P, Casabella A, Paolino S, Pizzorni C, Sulli A, Smith V, Cutolo M. The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: A systematic review. Autoimmun Rev 2024; 23:103637. [PMID: 39255852 DOI: 10.1016/j.autrev.2024.103637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2024] [Revised: 09/04/2024] [Accepted: 09/07/2024] [Indexed: 09/12/2024]
Abstract
BACKGROUND AND AIM Systemic sclerosis (SSc) is an immune mediated connective tissue disease characterized by microvascular dysfunction, aberrant immune response, and progressive fibrosis. Although the immuno-pathophysiological mechanisms underlying SSc are not fully clarified, they are often associated with a dysfunctional macrophage activation toward an alternative (M2) phenotype induced by cytokines [i.e., IL-4, IL-10, IL-13, and transforming growth factor (TGF-β)] involved in the fibrotic and anti-inflammatory process. A spectrum of macrophage activation state has been identified ranging from M1 to M2 phenotype, gene expression of phenotype markers, and functional aspects. This systematic review aims to analyze the importance of M2 macrophage polatization during the immune mediated process and the identification of specific pathways, cytokines, and chemokines involved in SSc pathogenesis. Moreover, this review provides an overview on the in vitro and in vivo studies aiming to test therapeutic strategies targeting M2 macrophages. METHODS A systematic literature review was performed according to the preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA). The search encompassed the online medical databases PubMed and Embase up to the 30th of June 2024. Original research manuscripts (in vitro study, in vivo study), animal model and human cohort, were considered for the review. Exclusion criteria encompassed reviews, case reports, correspondences, and conference abstracts/posters. The eligible manuscripts main findings were critically analyzed, discussed, and summarized in the correspondent tables. RESULTS Out of the 77 screened abstracts, 49 papers were deemed eligible. Following a critical analysis, they were categorized according to the primary (29 original articles) and secondary (20 original articles) research objectives of this systematic review. The data from the present systematic review suggest the pivotal role of M2 macrophages differentiation and activation together with the dysregulation of the immune system in the SSc pathogenesis. Strong correlations have been found between M2 macrophage presence and clinical manifestations in both murine and human tissue samples. Interestingly, the presence of M2 cell surface markers on peripheral blood monocytes has been highlighted, suggesting a potential biomarker role for this finding. Therapeutic effects reducing M2 macrophage activities have been observed and/or tested for existing and for new drugs, demonstrating potential efficacy in modulating the pro-fibrotic immune response for treatment of SSc. CONCLUSIONS The increased M2 macrophage activation in course of SSc seems to offer new insights on the self-amplifying inflammatory and fibrotic response by the immune system on such disease. Therefore, the revaluation of immunomodulatory and ongoing antifibrotic therapies, as well as novel therapeutical approaches in SSc that contribute to limit the M2 macrophage activation are matter of intense investigations.
Collapse
Affiliation(s)
- Rosanna Campitiello
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
| | - Stefano Soldano
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy.
| | - Emanuele Gotelli
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy
| | - Elvis Hysa
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; Department of Experimental Medicine (DIMES), University of Genova, Genova, Italy
| | - Paola Montagna
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy.
| | - Andrea Casabella
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
| | - Sabrina Paolino
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
| | - Carmen Pizzorni
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
| | - Alberto Sulli
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
| | - Vanessa Smith
- Department of Rheumatology, Ghent University Hospital, University of Ghent, Ghent, Belgium; Department of Internal Medicine, Ghent University Hospital, University of Ghent, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, Flemish Institute for Biotechnology, Inflammation Research Center, Ghent, Belgium.
| | - Maurizio Cutolo
- Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
| |
Collapse
|
2
|
Wen Y, Ren C, Zhu L, Huang L, Qi H, Yu W, Wang K, Zhao M, Xu Q. Unmasking of molecular players: proteomic profiling of vitreous humor in pathologic myopia. BMC Ophthalmol 2024; 24:352. [PMID: 39160465 PMCID: PMC11334356 DOI: 10.1186/s12886-024-03584-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2024] [Accepted: 07/18/2024] [Indexed: 08/21/2024] Open
Abstract
BACKGROUND This study aimed to identify the differentially expressed proteins in the vitreous humor (VH) of eyes with and without pathologic myopia (PM), providing insights into the molecular pathogenesis. METHODS A cross-sectional, observational study was conducted. VH samples were collected from patients undergoing vitrectomy for idiopathic epiretinal membrane (ERM), macular hole (MH), or myopic retinoschisis (MRS). Label-free quantitative proteomic analysis identified differential protein expression, with validation using ELISA. RESULTS The proteomic profiling revealed significantly higher expressions of tubulin alpha 1a (TUBA1A) and eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) in PM groups (MH-PM, MRS-PM) compared to controls (MH, ERM). Conversely, xylosyltransferase 1 (XYLT1), versican core protein (VCAN), and testican-2 (SPOCK2) expressions were lower in PM. ELISA validation confirmed these findings. CONCLUSIONS Our study provides novel insights into the molecular mechanisms of PM. The differentially expressed proteins EEF1A1, TUBA1A, XYLT1, VCAN, and SPOCK2 may play crucial roles in chorioretinal cell apoptosis, scleral extracellular matrix (ECM) synthesis, and scleral remodeling in PM. These proteins represent potential new targets for therapeutic intervention in PM, highlighting the importance of further investigations to elucidate their functions and underlying mechanisms in disease pathogenesis.
Collapse
Affiliation(s)
- Yue Wen
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China
- College of Optometry, Peking University People's Hospital, Beijing, China
- Eye Disease and Optometry Institute, Beijing, China
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China
| | - Chi Ren
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China
- College of Optometry, Peking University People's Hospital, Beijing, China
- Eye Disease and Optometry Institute, Beijing, China
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China
| | - Li Zhu
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China
- College of Optometry, Peking University People's Hospital, Beijing, China
- Eye Disease and Optometry Institute, Beijing, China
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China
| | - Lvzhen Huang
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China
- College of Optometry, Peking University People's Hospital, Beijing, China
- Eye Disease and Optometry Institute, Beijing, China
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China
| | - Huijun Qi
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China
- College of Optometry, Peking University People's Hospital, Beijing, China
- Eye Disease and Optometry Institute, Beijing, China
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China
| | - Wenzhen Yu
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China
- College of Optometry, Peking University People's Hospital, Beijing, China
- Eye Disease and Optometry Institute, Beijing, China
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China
| | - Kai Wang
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China
- College of Optometry, Peking University People's Hospital, Beijing, China
- Eye Disease and Optometry Institute, Beijing, China
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China
| | - Mingwei Zhao
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China.
- College of Optometry, Peking University People's Hospital, Beijing, China.
- Eye Disease and Optometry Institute, Beijing, China.
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China.
| | - Qiong Xu
- Department of Ophthalmology, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Peking University People's Hospital, Beijing, China.
- College of Optometry, Peking University People's Hospital, Beijing, China.
- Eye Disease and Optometry Institute, Beijing, China.
- Peking University Health Science Center, No. 11 South Avenue of XiZhiMen, Xi Cheng District, 100044, Beijing, China.
| |
Collapse
|
3
|
Zhou L, He Y, Deng Y, Li X, Wang W, Chen J. Ciclopirox mitigates inflammatory response in LPS-induced septic shock via inactivation of SORT1-mediated wnt/β-Catenin signaling pathway. Immunopharmacol Immunotoxicol 2023; 45:701-708. [PMID: 37606515 DOI: 10.1080/08923973.2023.2231628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 06/23/2023] [Indexed: 08/23/2023]
Abstract
OBJECTIVE Septic shock, the most severe stage of sepsis, is a deadly inflammatory disorder with high mortality. Ciclopirox (CPX) is a broad-spectrum antimycotic agent which also exerts anti-inflammatory effects in human diseases. However, whether CPX can relieve inflammatory response in LPS-induced septic shock remains unclear. MATERIALS AND METHODS Male C57BL/6 mice LPS were injected intraperitoneally with LPS to simulate septic shock in vivo. RAW264.7 cells and bone marrow-derived macrophages (BMDMs) were subject to LPS treatment to simulate septic shock in vitro. ELISA was applied to detect the level of pro-inflammatory cytokines. Cell viability was assessed by CCK-8 assay. Protein levels was detected by western blotting. RESULTS CPX enhanced the survival rate and attenuated inflammation in mice with LPS-induced septic shock. Similarly, CPX dose-dependently mitigated LPS-induced inflammation in BMDMs. It was also found that Sortilin 1 (SORT1) was upregulated in both in vivo and in vitro models of LPS-induced septic shock. In addition, SORT1 overexpression counteracted the alleviative effects of CPX on the inflammation response of LPS-challenged BMDMs by activating the Wnt/β-Catenin signaling. Furthermore, BML-284 (a Wnt/β-Catenin agonist) treatment also abrogated CPX-mediated moderation of LPS-triggered inflammatory reaction in BMDMs. CONCLUSIONS In sum, we found that CPX protected against LPS-induced septic shock by mitigating inflammation via SORT1-mediated Wnt/β-Catenin signaling pathway.
Collapse
Affiliation(s)
- Liangliang Zhou
- Department of Emergency Intensive Care Medicine and Department of Emergency Medicine, The Fourth Affiliated Hospital of Nantong University/The First People's Hospital of Yancheng, Yancheng, Jiangsu, China
| | - Yingfeng He
- Department of Emergency Intensive Care Medicine, The Fourth Affiliated Hospital of Nantong University/The First People's Hospital of Yancheng, Yancheng, Jiangsu, China
| | - Yijun Deng
- Department of Emergency Intensive Care Medicine, The Fourth Affiliated Hospital of Nantong University/The First People's Hospital of Yancheng, Yancheng, Jiangsu, China
| | - Xinxin Li
- Department of Emergency Intensive Care Medicine, The Fourth Affiliated Hospital of Nantong University/The First People's Hospital of Yancheng, Yancheng, Jiangsu, China
| | - Wei Wang
- Department of Emergency Intensive Care Medicine, The Fourth Affiliated Hospital of Nantong University/The First People's Hospital of Yancheng, Yancheng, Jiangsu, China
| | - Jianjun Chen
- Department of Emergency Intensive Care Medicine and Department of Emergency Medicine, The Fourth Affiliated Hospital of Nantong University/The First People's Hospital of Yancheng, Yancheng, Jiangsu, China
| |
Collapse
|
4
|
Ly TD, Wolny M, Lindenkamp C, Birschmann I, Hendig D, Knabbe C, Faust-Hinse I. The Human Myofibroblast Marker Xylosyltransferase-I: A New Indicator for Macrophage Polarization. Biomedicines 2022; 10:2869. [PMID: 36359389 PMCID: PMC9687871 DOI: 10.3390/biomedicines10112869] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/29/2022] [Accepted: 11/05/2022] [Indexed: 09/04/2023] Open
Abstract
Chronic inflammation and excessive synthesis of extracellular matrix components, such as proteoglycans (PG), by fibroblast- or macrophage-derived myofibroblasts are the hallmarks of fibrotic diseases, including systemic sclerosis (SSc). Human xylosyltransferase-I (XT-I), which is encoded by the gene XYLT1, is the key enzyme that is involved in PG biosynthesis. Increased cellular XYLT1 expression and serum XT-I activity were measured in SSc. Nothing is known so far about the regulation of XT-I in immune cells, and their contribution to the increase in measurable serum XT-I activity. We utilized an in vitro model, with primary human CD14+CD16+ monocyte-derived macrophages (MΦ), in order to investigate the role of macrophage polarization on XT-I regulation. The MΦ generated were polarized towards two macrophage phenotypes that were associated with SSc, which were classified as classical pro-inflammatory (M1-like), and alternative pro-fibrotic (M2-like) MΦ. The fully characterized M1- and M2-like MΦ cultures showed differential XT-I gene and protein expressions. The fibrotic M2-like MΦ cultures exhibited higher XT-I secretion, as well as increased expression of myofibroblast marker α-smooth muscle actin, indicating the onset of macrophage-to-myofibroblast transition (MMT). Thus, we identified XT-I as a novel macrophage polarization marker for in vitro generated M1- and M2-like MΦ subtypes, and broadened the view of XT-I as a myofibroblast marker in the process of MMT.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Isabel Faust-Hinse
- Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Georgstraße 11, 32545 Bad Oeynhausen, Germany
| |
Collapse
|